Searle & Co’s Takeda Pharmaceutical TAK Stock Holding History

Searle & Co’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-31,697	Closed	-$454K	–	156
2022 Q1	$454K	Sell	31,697 -70	-0.2%	-$1.03K	0.17%	108
2021 Q4	$433K	Hold	31,767	–	–	0.16%	109
2021 Q3	$520K	Hold	31,767	–	–	0.21%	88
2021 Q2	$535K	Sell	31,767 -1,641	-5%	-$27.9K	0.22%	90
2021 Q1	$610K	Sell	33,408 -3,523	-10%	-$63.4K	0.27%	80
2020 Q4	$672K	Buy	36,931 +70	+0.2%	+$1.23K	0.32%	75
2020 Q3	$658K	Hold	36,861	–	–	0.36%	69
2020 Q2	$661K	Hold	36,861	–	–	0.38%	71
2020 Q1	$560K	Hold	36,861	–	–	0.4%	68
2019 Q4	$727K	Sell	36,861 -168	-0.5%	-$3.21K	0.4%	68
2019 Q3	$637K	Sell	37,029 -167	-0.4%	-$2.89K	0.38%	70
2019 Q2	$658K	Hold	37,196	–	–	0.4%	66
2019 Q1	$758K	Buy	+37,196	New	+$748K	0.47%	60

Other funds holding TAK

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Searle & Co's TAK Position: Q2 2022 in Review

Searle & Co sold out of Takeda Pharmaceutical (TAK) in Q2 2022, closing a stake of 31,697 shares — an estimated $454K sold.

Searle & Co first reported a position in TAK in Q1 2019 and held it in 13 quarters. The position peaked at $758K in Q1 2019. 283 funds tracked by Wall St. Rank hold TAK as of Q2 2022.

Searle & Co reported no remaining Takeda Pharmaceutical position as of Q2 2022 after selling out during the quarter.
Searle & Co sold 31,697 Takeda Pharmaceutical shares in Q2 2022, an estimated $454K.
Searle & Co first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 13 quarters.
Searle & Co's Takeda Pharmaceutical position peaked at $758K in Q1 2019.
283 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2022.

Based on Searle & Co's 13F filing for Q2 2022, filed 3 Aug 2022.